Handheld Device Assesses Head Trauma Patients

By leveraging state-of-the-art smartphone-based technology and a proprietary disposable electrode headset, the Ahead 300 can provide rapid, objective assessment of the likelihood of the presence of TBI in patients who present with mild symptoms at the point of care. The device can also provide a digitized, streamlined report detailing a comprehensive and objective panel of results to facilitate differential diagnosis.

Developed in partnership with the U.S. Department of Defense (DOD; Washington, DC, USA), the system consists of a monitoring handset, dedicated software and algorithms for EEG acquisition and analysis and patient stratification, a disposable electrode headset, and a web-based application for centralized storage and review of patient data. The Ahead 300 is a product of Brainscope (Bethesda, MD, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

“The Ahead 300 provides the specific capabilities needed today for the clinician to undertake a comprehensive assessment addressing the full spectrum of traumatic brain injury, from structural injuries visible on a CT scan, through mild TBI, also known as concussion,” said Michael Singer, CEO of BrainScope. “Our FDA clearance represents many years of development with our partner, the DOD. We are particularly grateful for the strong, continuing partnership which has led to this outstanding outcome.”

Head injury is the leading cause of death and disability in people under 45 years of age in developed countries, mostly resulting from falls and road accidents. The primary injury is caused by the initial mechanical force, which is followed by a secondary injury that develops in the hours and days afterwards, which is largely responsible for the patients' subsequent mental and physical disabilities.

Related Links:
U.S. Department of Defense
Brainscope